Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

Carl Zeiss Meditec AG, DE0005313704

Carl Zeiss Meditec AG, DE0005313704

19.04.2021 - 10:10:05

Carl Zeiss Meditec AG returns to significant revenue growth in second quarter 2020/21

Carl Zeiss Meditec AG returns to significant revenue growth in second quarter 2020/21 Jena, April 19, 2021 Carl Zeiss Meditec AG (ISIN: DE0005313704) has achieved revenue of EUR 767.4 million in the first half of fiscal year 2020/21 (previous year: EUR 714.9 million). This corresponds to a revenue development of +7.3% vs. the past year (after adjustment for currency effects[1]: +10.5%). In the second quarter of FY 2020/21, revenue amounted to EUR 398.5 million (past year: EUR 345.3 million) - a growth rate of +15.4% (after adjustment for currency effects: +18.8%). Earnings before interest and taxes (EBIT)[2] amounted to EUR 162.7 million in the first half of FY 2020/21 (past year: EUR 102.5 million). EBIT margin (EBIT / revenue) was 21.2% (past year 14.3%). In the second quarter of FY 2020/21, EBIT amounted to EUR 89.3 million (past year: EUR 45.7 million). EBIT margin was 22.4% (past year: 13.2%). EBIT benefitted in part from a favorable development of product mix as well as a continuing low level of sales and marketing expenses due to the COVID-19 pandemic, compared to the past year. Earnings per share (EPS)[3] amounted to EUR 1.12 (past year: EUR 0.71) for the first half of FY 2020/21. In the second quarter, EPS amounted to EUR 0.60 (past year: EUR 0.28). Full results for the first half 2020/21 will be published on May 10, 2021. During the further course of FY 2020/21, the company expects an ongoing normalization of business development. This expectation is based on the assumption that there will be no renewed deterioration in the global pandemic situation. Revenue is expected to reach around EUR 1.6 billion (past year: EUR 1,335.5 million) in FY 2020/21. EBIT margin for FY 2020/21 is projected to reach a level of approximately 20% (past year: 13.3%), with significant support from lower than usual sales and marketing expenses in the current year. The company's mid-term margin outlook remains unchanged: to generate an EBIT margin sustainably above the level of 18%. ? ?

?

Contact for investors and press Sebastian Frericks Head of Investor Relations Carl Zeiss Meditec AG Tel.: +49 3641 220-116 E-Mail: investors.meditec@zeiss.com

?

[1] Currency-adjusted revenue growth is determined by weighing sales in the comparative period with current instead of actual historical exchange rates.[2] Earnings before interest and taxes (also operating profit, EBIT) refers to a key earnings figure within the Carl Zeiss Meditec Group and is calculated in accordance with IFRS standards (see Annual Report 2019/20, p. 78 for reconciliation).[3] Earnings per share (also EPS) refers to a key earnings figure within the Carl Zeiss Meditec Group and is calculated according to IFRS standards (see Annual Report 2019/20, p. 78 for reconciliation).

19-Apr-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language: English Company: Carl Zeiss Meditec AG G?schwitzer Str. 51-52 07745 Jena, Germany

Germany Phone: +49 (0)3641 220-0 Fax: +49 (0)3641 220-112 E-mail: investors.meditec@zeiss.com Internet: www.zeiss.de/meditec-ag/ir ISIN: DE0005313704 WKN: 531370 Indices: MDAX, TecDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1186148 ? End of Announcement DGAP News Service

1186148??19-Apr-2021?CET/CEST

@ dgap.de